NCT06649656 - A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Cancers

Interventions

DRUG

TQB2252 injection

TQB2252 injection is a compound preparation of TQB2223 monoclonal antibody (LAG-3) and penpulimab (PD-1), with a specification of 300mg TQB2223 monoclonal antibody and 100mg (20ml) penpulimab per bottle.

Trial Locations (1)

519041

Guangdong provincial people's hospital, Guangzhou